Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds bacterium or component thereof or substance produced...
Reexamination Certificate
2011-08-30
2011-08-30
Ogunbiyi, Oluwatosin (Department: 1645)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds bacterium or component thereof or substance produced...
C424S130100, C424S134100, C424S164100, C424S190100, C424S234100, C424S237100, C424S243100, C530S350000, C530S389500, C530S825000
Reexamination Certificate
active
08007803
ABSTRACT:
The present invention provides isolated polypeptides isolatable from aStaphylococcusspp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.
REFERENCES:
patent: 4981685 (1991-01-01), Healey
patent: 5538733 (1996-07-01), Emery et al.
patent: 5830479 (1998-11-01), Emery et al.
patent: 5906826 (1999-05-01), Emery et al.
patent: 6027736 (2000-02-01), Emery et al.
patent: 6288214 (2001-09-01), Höök et al.
patent: 6432412 (2002-08-01), Emery et al.
patent: 6680195 (2004-01-01), Patti et al.
patent: 6682754 (2004-01-01), Emery et al.
patent: 6692739 (2004-02-01), Patti et al.
patent: 6703025 (2004-03-01), Patti et al.
patent: 6720160 (2004-04-01), Wolde-Mariam
patent: 6841154 (2005-01-01), Foster et al.
patent: 7148191 (2006-12-01), Egyed et al.
patent: 2003/0036639 (2003-02-01), Emery et al.
patent: 2003/0064073 (2003-04-01), Emery et al.
patent: 2003/0186364 (2003-10-01), Bailey et al.
patent: 2003/0206922 (2003-11-01), Emery et al.
patent: 2003/0211118 (2003-11-01), Emery et al.
patent: 2004/0197350 (2004-10-01), Emery et al.
patent: 2004/0197869 (2004-10-01), Emery et al.
patent: 2004/0265329 (2004-12-01), Emery et al.
patent: 2005/0095682 (2005-05-01), Straub et al.
patent: 2005/0186217 (2005-08-01), Emery et al.
patent: 2006/0024323 (2006-02-01), Emery et al.
patent: 2006/0165718 (2006-07-01), Emery et al.
patent: 2006/0233824 (2006-10-01), Emery et al.
patent: 2007/0087011 (2007-04-01), Emery et al.
patent: 2007/0128183 (2007-06-01), Meinke et al.
patent: 2008/0200650 (2008-08-01), Emery et al.
patent: WO 90/12591 (1990-11-01), None
patent: WO 95/21627 (1995-08-01), None
patent: WO 96/01620 (1996-01-01), None
patent: WO 01/37810 (2001-05-01), None
patent: WO 01/37810 (2001-05-01), None
patent: WO 01/37810 (2001-11-01), None
patent: WO 02/053180 (2002-07-01), None
patent: WO 02/094868 (2002-11-01), None
patent: WO 02/053180 (2003-03-01), None
patent: WO 03/020875 (2003-03-01), None
patent: WO 03/020875 (2003-10-01), None
patent: WO 2004/013166 (2004-02-01), None
patent: WO 2004/013166 (2004-04-01), None
patent: WO 2006/021893 (2006-03-01), None
patent: WO 2006/021893 (2006-06-01), None
patent: WO 2006/088803 (2006-08-01), None
patent: WO 2006/088803 (2006-12-01), None
Mendoza et al. lnternation Journal of Systemic Bacteriology (1988), 48, 1049-1055.
Verhoef et al. Eur. J. Clin. Microbiol. Infect Dis., Apr. 1990, p. 247-250.
Domanski et al. Infection and Immunity, Aug. 2005, p. 5229-5232.
Todar's Online Textbook of Bacteriology, 2002. Retrieved May 11, 2007 from http://www.textbookofbacteriology.net
ormalflora.html.
Poutrel et al. Journal of Clinical Microbiology, Feb. 1990, p. 358-360.
Mendoza et al . Journal of Systemic Bacteriology, 1988, 38: 1049-1055 p. 1051.
Projan et al. Current Opinion in Pharmacology 2006, 6: 473-479.
Kaplan et al. The Pediatric Infectious Diseases Journal vol. 24 (5) May 2005 p. 457-458.
Anstead et al. Curr Opin Infect 17:549-555, 2004.
Pengov et al (J. of Dairy Sci. 86:3157-3163, 2003).
Anneke van der Zee et al (Journal of Clinical Microbiology, Feb. 1999, p. 342-349).
Ando et al., “Characterization of the Role of the Divalent Metal Ion-Dependent Transcriptional Repressor MntR in the Virulence ofStaphylococcus aureus” Infect. Immun., May 2003; 71(5):2584-90.
Baker et al., “Intravenous immune globulin for the prevention of nosocomial infection in low-birth-weight neonates,”N. Engl. J. Med., Jul. 23, 1992; 327(4):213-9.
Bloom et al., “Multicenter Study to Assess Safety and Efficacy of INH-A21, a Donor-Selected Human Staphyococcal Immunoglobulin, for Prevention of Nosocomial Infections in Very Low Birth Weight Infants,”Pediatr Infect Dis J., Oct. 2005; 24(10):858-66.
Boulianne et al., “Production of functional chimacric mouse/human antibody,”Nature, Dec. 13-19, 1984; 312(5995):643-6.
Brouillette et al., “DNA immunization against the clumping factor A (ClfA) ofStaphylococcus aureus,” Vaccine, May 22, 2002; 20(17-18):2348-57.
Bruggernan et al., “Production of human antibody repertoires in transgenic mice,”Curr. Opin. Biotechnol., Aug. 1997; 8(4):455-8.
Brown et al., “Characterization of Pit, aStreptococcus pneumoniaeIron Uptake ABC Transporter”Infect. Immun., Aug. 2002; 70(8):4389-98.
Bunce et al., “Murine Model of Cutaneous Infection with Gram-Positive Cocci”Infect. Immun., Jul. 1992; 60(7):2636-40.
Capparelli et al., “Multicenter Study to Determine Antibody Concentrations and Assess the Safety of Administration of INH-A2I, a Donor-Selected Human Staphylococcal Immune Globulin, in Low-Birth-Weight Infants,”Antimicrob Agents Chemother., Oct. 2005; 49(10):4121-7.
Clarke et al., “IsdA ofStaphylococcus aureusis a broad spectrum, iron-regulated adhesin”Mol. Microbiol., Mar. 2004; 51(5):1509-19.
Cockayne et al., “Molecular Cloning of a 32-Kilodalton Lipoprotein Component of a Novel Iron-RegulatedStaphylococcus epidermidisABC Transporter”Infect. Immun., Aug. 1998; 66(8):3767-74.
Courcol et al., “Effects of iron depletion and sub-inhibitory concentrations of antibiotics on siderophore production byStaphylococcus aureus,” Journal of Antimicrobial Chemotherapy, 1991; 28:663-668.
Courcol et al., “Siderophore production byStaphylococcus aureusand identification of iron-regulated proteins”Infection and Immunity, May 1997; 65(5):1944-8.
Dale et al., “Role of Siderophore Biosynthesis in Virulence ofStaphylococcus aureus: Identification and Characterization of Genes Involved in Production of a Siderophore”Infect. Immun., Jan. 2004; 72(1):29-37.
Dale et al., “Involvement of SirABC in Iron-Siderophore Import inStaphylococcus aureus” J. Bacteriol., Dec. 2004; 186(24):8356-62.
Darenberg et al., “Differences in Potency of Intravenous Polyspecific Immunoglobulin G Against Streptococcal and Staphylococcal Superantigens: Implications for Therapy of Toxic Shock Syndrome,”Clin Infect Dis., Mar. 15, 2004; 38(6):836-42.
Daugherty et al., “Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD]8 component of leukocyte integrins,”Nucleic Ada Res., May 11, 1991; 19(9):2471-6.
Diarra et al., “Response ofStaphylococcus aureusIsolates from Bovine Mastitis to Exogenous Iron Sources”J. Dairy Sci., 2002; 85(9):2141-8.
Domanski et al., “Characterization of a Humanized Monoclonal Antibody Recognizing Clumping Factor A Expressed byStaphylococcus aureus,” Infect. Immun., Aug. 2005; 73(8):5229-32.
Drechsel et al., “Purification and chemical characterization of staphyloferrin B, a hydrophilic siderophore from staphylococci”Biometals, 1993; 6:185-92.
Dryla et al., “Identification of a novel iron regulated staphylococcal surface protein with haptoglobin-haemoglobin binding activity”Mol. Microbiol., Jul. 2003; 49(1):37-53.
Durfee, “Classification of 110 Strains ofStaphylococcus aureus” J. Bacteriol., Nov. 1942; 44(5):589-95.
Fattom et al., “Developement of StaphVAX, a polysaccharide conjugate vaccine againstS. aureusinfection: from the lab bench to phase III clinical trials,”Vaccine, Feb. 17, 2004; 22(7):880-7.
Foster et al., “Surface protein adhesins ofStaphylococcus aureus” Trends Microbiol., 1998; 6:Title page, Publication page, and pp. 484-488.
Gampfer et al., “Epitope mapping of neutralizing TSST-1 specific antibodies induced by immunization with toxin or toxoids,”Vaccine, Nov. 1, 2002; 20(31-32):3675-84.
Geret et al., “Vaccination against staphylococcal infections in animal experiments,”Helvetica Chirurgica Acta, 1979; 46(1-2):167-169.
Hall et al., “Characterization of a Protective Monoclonal Antibody RecognizingStaphylococcus aureusMSCRAMM Protein Clumping Factor A,”Infect. Immun., Dec. 2003; 71(12):6864-70.
Harlow
Emery Daryll A.
Herron Olson Lisa L.
Straub Darren E.
Wonderling Laura
Epitopix LLC
Mueting Raasch & Gebhardt, P.A.
Ogunbiyi Oluwatosin
LandOfFree
Polypeptides and immunizing compositions containing gram... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polypeptides and immunizing compositions containing gram..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polypeptides and immunizing compositions containing gram... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2680813